A study to compare two different aramchol formulations in healthy volunteers.

2023-507445-28-00 Protocol CGA23001 Human pharmacology (Phase I) - Other Ended

Start 18 Dec 2024 · End 12 Jun 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CGA23001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 16
Countries 1
Sites 1

Nonalcoholic fatty liver disease

Key facts

Sponsor
CCDRD Cooperative Clinical Drug Research and Development AG, Galmed Research And Development Ltd.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
18 Dec 2024 → 12 Jun 2025
Decision date (initial)
2024-12-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-507445-28-00
ClinicalTrials.gov
NCT06502561

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Nonalcoholic fatty liver disease

VersionLevelCodeTermSystem organ class
24.1 PT 10053219 Non-alcoholic steatohepatitis 100000004871
25.0 LLT 10082249 Nonalcoholic fatty liver disease 100000004871
20.1 LLT 10036732 Primary sclerosing cholangitis 10019805

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CCDRD Cooperative Clinical Drug Research and Development AG

Sponsor organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Address
Lindenallee 70, Dahlwitz-Hoppegarten Dahlwitz-Hoppegarten
City
Hoppegarten
Postcode
15366
Country
Germany

Scientific contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Sacha Arsova

Public contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Sacha Arsova

Galmed Research And Development Ltd.

Sponsor organisation
Galmed Research And Development Ltd.
Address
16 Tiomkin
City
Tel Aviv-Yafo
Postcode
6578317
Country
Israel

Scientific contact point

Organisation
Galmed Research And Development Ltd.
Contact name
Yossi Gilgun-Sherki

Public contact point

Organisation
Galmed Research And Development Ltd.
Contact name
Yossi Gilgun-Sherki

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 16 1
Rest of world 0

Investigational sites

Bulgaria

1 site · Ended
Bed space for short term stay at Diagnostic & Consultative Centre 'Ascendent' Ltd.
Bed space for short term stay, 47 'Bacho Kiro' str., 1202, Sofia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2024-12-18 2025-06-12 2024-12-18 2025-05-21

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-09 Bulgaria Acceptable
2024-12-09
2024-12-13